Skip navigation

Chemical Butyrates

These are exposure studies associated with the chemical and all of its children.

Send correction
  Reference Associated Study Title Author's Summary Study Factors Stressor Receptors Country Medium Exposure Marker Measurements Outcome
1. O'Connor P, et al. (2016). Teriflunomide Multiple Sclerosis Oral (TEMSO) Study In the Teriflunomide Multiple Sclerosis Oral extension, safety observations were consistent with the core trial, with no new or unexpected adverse events in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide. teriflunomide Subjects with disease:Multiple Sclerosis Austria|Canada|
Chile|Czech Republic|
Denmark|Estonia|
Finland|France|
Germany|Italy|
Netherlands|Norway|
Poland|Portugal|
Russian Federation|Sweden|
Switzerland|Turkey|
Ukraine|United Kingdom|
United States
teriflunomide Details Multiple Sclerosis